永顺生物(839729) - 2025 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2025 was ¥7,916,030.82, a decrease of 5.47% year-on-year[8]. - Operating revenue for Q1 2025 was ¥65,456,650.96, down 1.56% from ¥66,495,478.87 in Q1 2024[8]. - The net profit for the first quarter of 2025 is 7,916,030.82, a decrease of 5.48% compared to 8,374,511.51 in the same period of 2024[35]. - The total profit for the first quarter of 2025 is 8,711,054.06, down from 9,420,501.30 in the first quarter of 2024, representing a decline of 7.51%[35]. - The operating profit for the first quarter of 2025 is 8,718,430.12, slightly lower than 9,360,944.99 in the same period of 2024[35]. - Basic and diluted earnings per share remain unchanged at 0.03 for both the first quarter of 2025 and 2024[36]. - The total comprehensive income attributable to the parent company for the first quarter of 2025 is 7,916,030.82, compared to 8,374,511.51 in the first quarter of 2024[36]. Assets and Liabilities - Total assets as of March 31, 2025, reached ¥789,010,699.45, an increase of 3.76% compared to the end of the previous year[8]. - Current assets totaled CNY 601,207,705.58 as of March 31, 2025, up from CNY 564,818,676.77 at the end of 2024, reflecting a growth of 6.45%[31]. - Total assets increased to CNY 789,010,699.45 as of March 31, 2025, compared to CNY 760,429,656.42 at the end of 2024, marking a growth of 3.92%[32]. - Total liabilities rose to CNY 118,259,419.58 as of March 31, 2025, compared to CNY 99,800,423.50 at the end of 2024, indicating a significant increase of 18.43%[33]. - The total liabilities to assets ratio remained stable at 14.99% for both the parent and consolidated entities[8]. Cash Flow - The company's cash flow from operating activities increased by 3.35% to ¥17,062,453.70 compared to the same period last year[8]. - The cash flow from operating activities for the first quarter of 2025 is 17,062,453.70, an increase from 16,510,126.57 in the first quarter of 2024[36]. - The total cash outflow from operating activities in the first quarter of 2025 is 46,336,875.46, compared to 51,340,444.49 in the first quarter of 2024[36]. - The cash inflow from investment activities in the first quarter of 2025 is 120,362,370.26, significantly higher than 46,599,181.42 in the same period of 2024[36]. - The net cash flow from investment activities for the first quarter of 2025 is -46,677,987.64, compared to a positive 15,594,454.42 in the first quarter of 2024[37]. - Cash and cash equivalents decreased to CNY 22,468,586.94 from CNY 36,593,830.46, a decline of 38.67%[31]. - The cash and cash equivalents at the end of the first quarter of 2025 amount to 22,318,586.94, down from 205,772,155.39 at the end of the first quarter of 2024[37]. Shareholder Information - The largest shareholder, Guangdong Provincial Agricultural Group, holds 106,780,769 shares, accounting for 39.06% of the total shares[17]. - The second largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 53,872,000 shares, representing 19.71% of the total shares[17]. - The third largest shareholder, Guangdong Academy of Agricultural Sciences Animal Health Research Institute, holds 30,799,999 shares, which is 11.27% of the total shares[17]. - There are no pledges or judicial freezes on shares held by shareholders with more than 5% ownership[19]. - The company has no ongoing litigation, arbitration, or external guarantees during the reporting period[21]. - The company has fulfilled all previously disclosed commitments without any overdue situations[28]. Stock Information - The total number of unrestricted shares decreased from 80,425,041 to 76,825,041, representing a change of -3,600,000 shares, which is a reduction of approximately 4.48%[14]. - The total number of restricted shares increased from 192,924,959 to 196,524,959, reflecting an increase of 3,600,000 shares, which is an increase of about 1.87%[14]. - The total share capital remains unchanged at 273,350,000 shares[14]. - The company implemented a stock incentive plan in 2024, granting 3,600,000 restricted shares to 33 individuals, which is approximately 1.32% of the total share capital[24]. Expenses - The company's financial expenses increased by 89.18% to -¥107,316.35, primarily due to adjustments in financial product structures[10]. - Total operating costs for Q1 2025 were CNY 58,827,999.72, an increase of 2.19% from CNY 57,569,882.86 in Q1 2024[34]. - R&D expenses for Q1 2025 were CNY 5,153,474.56, slightly down from CNY 5,350,715.65 in Q1 2024[34]. - The company experienced a 337.53% increase in other payables, reaching ¥18,352,203.48, mainly due to equity incentive contributions[10]. - Non-recurring gains and losses for the period amounted to ¥2,535,421.70 after tax[12].